Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2013 2
2014 2
2015 1
2017 3
2018 4
2019 2
2020 6
2021 11
2022 8
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Impact of severe acute kidney injury on short-term mortality in urosepsis.
Fujita N, Momota M, Soma O, Noro D, Mikami J, Miura Y, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C, Hatakeyama S. Fujita N, et al. Among authors: noro d. World J Urol. 2024 May 8;42(1):301. doi: 10.1007/s00345-024-05018-w. World J Urol. 2024. PMID: 38717511
Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
Fujita N, Hatakeyama S, Tabata R, Okita K, Kido K, Hamano I, Tanaka T, Noro D, Tokui N, Suzuki Y, Yoneyama T, Hashimoto Y, Sato S, Ohyama C. Fujita N, et al. Among authors: noro d. Prostate Int. 2024 Mar;12(1):46-51. doi: 10.1016/j.prnil.2023.12.002. Epub 2023 Dec 19. Prostate Int. 2024. PMID: 38523900 Free PMC article.
Machine learning diagnosis by immunoglobulin N-glycan signatures for precision diagnosis of urological diseases.
Iwamura H, Mizuno K, Akamatsu S, Hatakeyama S, Tobisawa Y, Narita S, Narita T, Yamashita S, Kawamura S, Sakurai T, Fujita N, Kodama H, Noro D, Kakizaki I, Nakaji S, Itoh K, Tsuchiya N, Ito A, Habuchi T, Ohyama C, Yoneyama T. Iwamura H, et al. Among authors: noro d. Cancer Sci. 2022 Jul;113(7):2434-2445. doi: 10.1111/cas.15395. Epub 2022 May 25. Cancer Sci. 2022. PMID: 35524940 Free PMC article.
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.
Okuyama Y, Hatakeyama S, Numakura K, Narita T, Tanaka T, Miura Y, Sasaki D, Noro D, Tokui N, Okamoto T, Yamamoto H, Narita S, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C. Okuyama Y, et al. Among authors: noro d. BJUI Compass. 2021 Oct 8;3(2):154-161. doi: 10.1002/bco2.118. eCollection 2022 Mar. BJUI Compass. 2021. PMID: 35474728 Free PMC article.
The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.
Ozaki K, Hatakeyama S, Tanaka T, Noro D, Tokui N, Horiguchi H, Okuyama Y, Fujita N, Okamoto T, Okamoto A, Suzuki Y, Yamamoto H, Yoneyama T, Hashimoto Y, Ohyama C. Ozaki K, et al. Among authors: noro d. BJUI Compass. 2021 Oct 8;3(2):139-145. doi: 10.1002/bco2.119. eCollection 2022 Mar. BJUI Compass. 2021. PMID: 35474727 Free PMC article.
Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, Noro D, Tanaka T, Ito H, Okuyama Y, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Aoki M, Ohyama C. Sasaki D, et al. Among authors: noro d. Urol Oncol. 2022 Feb;40(2):64.e1-64.e8. doi: 10.1016/j.urolonc.2021.11.005. Epub 2021 Dec 30. Urol Oncol. 2022. PMID: 34973857
36 results